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Central nervous system involvement is a severe manifestation of sarcoidosis that often requires
aggressive immunosuppressive therapy. The most efficacious approach for refractory disease is
unknown.
We reviewed the cases of four subjects who demonstrated active progression of neurosarcoi-
dosis while under treatment with cyclophosphamide, and who were subsequently treated with
infliximab.
All four subjects demonstrated rapid and substantial reversal of their clinical course. Radio-
logic findings were concordant with the clinical responses. There were no notable toxicities.
Treatment with infliximab may be more effective than cyclophosphamide for refractory
central nervous system sarcoidosis. A larger, prospective study is warranted.
ª 2008 Elsevier Ltd. All rights reserved.Central nervous system (CNS) sarcoidosis, which occurs in
up to 5% of individuals with sarcoidosis, confers substantial
morbidity and may portend a poor prognosis.1,2 Treatment
of severe CNS sarcoidosis typically requires aggressive
immunosuppression. Corticosteroids are the mainstay ofntral nervous system, CNS;
ance imaging, MRI; Metho-
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8 Elsevier Ltd. All rights reservedtreatment, but there are patients whose disease continues
to progress despite therapy with corticosteroids and
immunosuppressants.
Tumor necrosis factor a (TNF-a), a key mediator of
sarcoidosis, has been tied to clinical course of the disease and
is a prerequisite for granuloma formation.3,4 Infliximab is
a chimericmonoclonal antibody that blocksTNF-abioactivity.
In vitro data suggest that it can also lyse TNF-a producing
cells, alter cytokine release and induce apoptosis.5,6
There have been several observational reports of beneficial
response to infliximab for refractory systemic sarcoidosis,7,8
including CNS sarcoidosis.9 However, the relative effective-
ness of infliximab compared to conventional cytotoxic
therapy has not been studied..
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in four individuals with severe neurosarcoidosis that was
refractory to treatment with steroids and cyclophospha-
mide. These examples afford an opportunity to indirectly
assess the role of infliximab in severe neurosarcoidosis.Patient 1
A 50-year-old Caucasian male presented with stiffness of
the neck and shoulder girdle muscles, and left arm weak-
ness. Magnetic resonance imaging (MRI) revealed a large
enhancing lesion abutting the cervical spinal cord and
multiple smaller lesions along the lower cervical spinal cordFigure 1 MRI findings for patient #1. Gadolinium-enhanced T1-we
encroaching on the upper cervical spinal cord (arrow), with extens
lesions in the lower cervical cord (arrowhead). Intraoperative findin
Fig. 1B shows a transverse T1-weighted post-contrast image that re
(arrow), with mild impingement on the pons and the right seven
demonstrate the MRI findings after treatment with infliximab.(Fig. 1). The dominant mass-like lesion was resected via
a suboccipital craniotomy, along with C1e3 and C6e7
laminectomies. Intraoperative findings included intradural
and extradural masses with extension into the cerebellar
fossa. Pathologic exam revealed multiple necrotizing and
non-necrotizing granulomas associated with chronic
inflammation. Special stains and cultures for acid-fast
bacilli and fungi were negative. The diagnosis of sarcoidosis
was substantiated when chest imaging revealed subcarinal
lymphadenopathy, leading to a confirmatory transbronchial
needle aspirate diagnosis.
After four weeks of treatment with prednisone at 60 mg/
day, no improvement was noted either symptomatically or
on MRI. Intravenous cyclophosphamide was added at thisighted sagittal view (1A) demonstrated a large enhancing mass
ion through the foramen magnum. There were also enhancing
gs revealed infiltration into the spinal cord and the nerve roots.
vealed an enhancing lesion in the right cerebellopontine angle
th and eighth cranial nerve root entry zone. Panels C and D
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three weeks.10 After six infusions (7.25 g total), there was
no symptomatic improvement, but diplopia and blurred
vision occurred, suggesting disease progression. A repeat
MRI (Fig. 1B) revealed new nodular thickening and
enhancement of the dura, as well as new intraparenchymal
changes suspicious for granulomatous involvement. Treat-
ment with high dose pulse intravenous solumedrol
(1000 mg/day for three days) resolved the diplopia but the
blurred vision persisted. At that point, the patient was
switched to infliximab (5 mg/kg) and methotrexate. By the
fourth infusion, there was complete resolution of the
blurred vision along with notable improvement in the left
upper extremity strength. An MRI obtained at that time
revealed resolution of the radiographic abnormalities in the
right cerebellopontine angle as well as of all the other
enhancing lesions in the brain and spinal cord (Fig. 1C
and D).
Currently, the patient has received a total of 13 inflix-
imab infusions. He has been completely weaned off pred-
nisone and has only modest left hand weakness remaining.Patient 2
A 36-year-old Caucasian female with longstanding head-
aches had an MRI that revealed a parasagittal mass at the
posterior aspect of the right frontal lobe. Diagnostic biopsy
via craniotomy demonstrated non-caseating granulomas
consistent with sarcoidosis. Besides headaches, the patient
had noted progressive symptoms of impaired short-term
memory, intermittent dyspraxia, and episodes of confusion
and vertigo. She received oral dexamethasone 8 mg three
times daily for a period of six weeks with no improvement.
Oral methotrexate 15 mg weekly was added; however, the
symptoms continued to progress and she developed bilat-
eral facial and lower extremity paresthesias. A repeat MRI
(Fig. 2A) revealed much more prominent dural enhance-
ment and soft tissue thickening at the right parietal vertex.
In response, her therapy was switched to IV cyclophos-
phamide infusions and prednisone 5e80 mg/day. Five
months later, she had not improved, and her course was
complicated by spontaneous cranial incision dehiscence
requiring operative repair. Cultures from the inflammatory
tissue discovered intraoperatively were negative, but
biopsies were not repeated.
Due to the lack of response to steroids and cyclophos-
phamide, infliximab (5 mg/kg) and oral methotrexate were
started. By the second infusion, the patient began to notice
improvement in the facial paresthesias. Her episodes of
confusion decreased and her speech started to improve.
Prednisone was gradually tapered to 5 mg daily. An MRIFigure 2 MRI findings for patient #2. A T1-weighted coronal
section from patient 2 shows dural enhancement and thick-
ening over the right parietal convexity (2A). This enhancement
also extended further anteriorly and inferiorly along the falx.
After the fourth infliximab infusion, there was a marked
decrease in the extent of the dural enhancement (2B), which
showed further improvement by the ninth infusion (2C).
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improvement in the dural enhancement. Except for some
residual headaches, her neurologic symptoms entirely
resolved.
To date, she has received a total of 13 infliximab infu-
sions without any adverse events, with a sustained
improvement in neurological symptoms. Attempts to
decrease the frequency of her infliximab infusions to every
six weeks led to recurrence of facial paresthesias. These
again abated when the infusion frequency was increased to
every four weeks. Prednisone continues at 5 mg daily. The
most recent MRI shows complete resolution of all prior
enhancing lesions.Patient 3
A 49-year-old female developed flashes, blurry vision, and
progressive color blindness in the right eye in 2002. She also
complained of new dyspnea on exertion and cough, but
these were not further assessed at that time. Her exam and
imaging were consistent with bilateral optic neuritis; she
was treated with empiric prednisone (up to 80 mg daily)
and methotrexate 10 mg weekly. Mild left optic neuritis
developed over the following two years, which precipitatedFigure 3 MRI findings for patient #4. Contrast-enhanced transver
extending through the orbital roof into the left frontal lobe. There
after the fourth infusion showed almost complete resolution of thea consult in our institution. Her visual acuity at that time
was 20/30 in the left eye and she had no light perception in
the right eye. An MRI showed bilateral optic neuritis. A right
optic nerve decompression was performed but the biopsy of
the optic nerve sheath was non-specific. A diagnosis of
probable CNS sarcoidosis was made on the basis of bron-
choalveolar lavage lymphocytosis (23% lymphocytes),
nodular infiltrates on the chest CT scan, negative stains and
cultures, and a consistent neuroradiologic picture. Her
therapy was changed to intravenous cyclophosphamide,
along with prednisone (20 mg/day). Over the ensuing eight
months, the left eye visual field defects progressed and her
acuity also decreased to 20/50. MRI again showed evidence
of bilateral optic neuritis.
The patient developed suicidal ideation due to her
medical condition. Theworsening of patient symptomswhile
on cyclophosphamide and prednisone prompted a switch to
infliximab and methotrexate. By the second infusion, she
noted a marked improvement in her vision. After the fourth
infusion, the exam revealed left visual acuity of 20/20 and
reversal of the visual field defects. A follow-up MRI showed
resolution of the optic nerve enhancement.
She currently has received 16 infliximab infusions and
her prednisone has been tapered to 10 mg/day. Her vision is
stable and she reports no new neurological symptoms.se (3A) and coronal (3B) MRI images demonstrated a large mass
was associated left eye proptosis. Follow-up imaging (3C and D)
orbital mass.
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A 49-year-old Caucasian woman with an 18-month history of
trigeminal neuralgia developed worsening pain and pares-
thesias in her left vertex descending down to her left orbit.
Physical exam revealed left eye proptosis and decreased
visual acuity. An MRI (Fig. 3A and B) showed a large left
orbital mass, extending through the orbital roof. Biopsy of
the mass revealed non-necrotizing granulomas consistent
with sarcoidosis, and all intraoperative cultures were
negative. A chest X-ray revealed bilateral hilar lymphade-
nopathy, and confirmatory left cervical lymph node aspi-
rate also suggested sarcoidosis. Over the ensuing months,
she was treated with corticosteroids, methotrexate and
oral cyclophosphamide (100 mg daily, total dose 13.2 g), all
without clinical benefit. She was then started on infliximab
infusions (3 mg/kg), with a notable improvement in pares-
thesias. A follow-up MRI performed after the fourth infusion
showed almost complete resolution of the orbital mass
(Fig. 3C and D). Mycophenolate 1000 mg BID was begun
prior to the fifth dose of infliximab and complete resolutionTable 1 Clinical features of the reported patients.
Patient 1 Patient 2
Manifestations Intra- and extradural
cervical mass
Meningitis
Left arm paresis and
leg weakness
Headaches
Neck pain/stiffness Paresthesias
Cognitive impa
Disease duration 10 Months 2.5 Years
Therapies prior
to CYC
CS CS
MTX
Prednisone dose
(mg/day)
10e60 5e80
Total CYC prior to
disease
progression
7.25 g (IV) 6.5 g (IV)
Seven infusions Seven infusions
Evidence of disease
progression on CYC
Sudden onset of
severe diplopia and
blurred vision
Cranial wound
dehiscence
Fatigue Progressing hea
and paresthesia
Continued paresis MRI progression
Clinical response on
infliximab
Diplopia resolved after
IV solumedrol
Paresthesias re
after #4 infusio
Blurred vision resolved
after fourth infusion,
along with steady
L UE improvement
HA dramaticall
Response evident
(infusion #)
4 4
Other treatment MTXþ pred MTX (elevation
leflunomideþ p
Steroids weaned?
(current dose)
Off Yes (5 mg)of the mass was noted following the eighth infusion of
infliximab. She is maintained only on mycophenolate
mofetil currently and has had no recurrence of her mass.Summary
There are no randomized controlled studies focusing on CNS
sarcoidosis on which to base treatment guidelines. Most
patients with significant central nervous system sarcoidosis
will exhibit a difficult course, and treatment is recom-
mended unless there is only isolated facial nerve palsy or
minimally symptomatic aseptic meningitis.11 Prolonged
courses of corticosteroids have been used most frequently;
some authors have suggested use of prednisone doses up to
1 mg/kg,11 although there are no controlled data to support
this recommendation. However, most series have found
that corticosteroid monotherapy is adequate in less than
half of patients.12,13 A range of alternatives have been used
in this setting, including methotrexate, azathioprine,
cyclophosphamide, cyclosporine, antimalarial agents, andPatient 3 Patient 4
Bilateral optic neuritis Trigeminal neuralgia
Complete unilateral
visual loss
Facial pain/paresthesias
Visual complaints
irment
3 Years 2.5 Years
CS CS
MTX MTX, AZA
20e60 5e40
13.5 g (IV) 12 g (oral)
12 Infusions 100 mg/day over
four months
Inexorable decline in
visual acuity
Progressive paresthesias
and visual complaints
daches
s
Concern for chiasmatic
involvement on exam
solved
n
L vision stabilized at
20/50 and visual field
normalized after
#1 infusion
Near resolution of
orbital mass on MRI
after fourth infusion
y better L vision 20/20 after
#3 infusion
1 4
LFTs)
red
MTXþ pred PredþMTX (tolerance)
/MMF
Yes (10 mg) Off
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mide may be the most effective of these10,13; cyclosporine
and chlorambucil are rarely used in the modern era.
The four patients reported here developed varying
manifestations of progressive CNS sarcoidosis that was
refractory to high dose steroids and standard cytotoxic
therapy. Not only did the patients fail to respond well to
a cyclophosphamide-based regimen previously shown to be
effective for CNS sarcoidosis,10 but also they actually
developed disease progression (Table 1).
All four patients responded to infliximab with dramatic
improvements in their neurological symptoms. Response
was evident early in the course of infliximab treatment,
with marked symptomatic improvement noted as early as
the second infusion in two patients and after the fourth
infusion in the other two patients. Radiologic follow-up
exams confirmed the clinical impressions. These effects
were probably not due to methotrexate, which generally
requires several months to effect significant change. Our
experience extends the prior literature by demonstrating
clinical superiority in a group of patients for infliximab
compared with the standard therapy for CNS sarcoidosis.
No serious infections or adverse events were noted in
any of our four patients. A potential concern relates to
post-marketing data associating exposure to TNF antago-
nists with the new onset of demyelinating disorders.14,15
These cases have been mainly described in patients treated
with the soluble receptor antagonist, etanercept.14 It is
unclear, however, whether the incidence of new demye-
lination is any higher than expected background rates.15
Any new neurologic symptom in patients treated with TNF
antagonists requires careful investigation with this
possibility in mind.
Our observations are consistent with the few prior case
reports and small case series of the beneficial effects of
infliximab therapy in patients with refractory systemic and
CNS sarcoidosis. Although most of the patients in the case
reports with CNS sarcoidosis described to have a positive
response to infliximab had visual symptoms and primarily
ocular inflammation, two of our patients had manifestations
other than ocular involvement and still experienced
dramatic benefit with infliximab. The fact that these
patients were actively progressing while on cytotoxic
therapy suggests that infliximab may be more efficacious
than cyclophosphamide for CNS sarcoidosis. The largest
reported experience with infliximab, a multicenter
randomized, placebo-controlled trial of 138 patients with
chronic sarcoidosis, included nine subjects with CNS
sarcoidosis.16,17 In general, physician assessment of the
treatment effect for these nine patients was modest.17
Possible explanations for the differences between these
data and our observations include the less aggressive dosing
regimen used in the trial, longer duration of disease (mean 7
years) in the trial subjects, and other baseline patient clin-
ical features that were not assessed in the trial. Prospective
controlled studies would be helpful to clarify the differential
benefit of TNF antagonists in CNS sarcoidosis.Conflict of interest statement
The authors have no conflicts of interest to disclose.
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